NYSE : NVO
Novo Nordisk A/S — Key statistics
Healthcare · Drug Manufacturers - General · Denmark
Last price 39.14 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 171.97B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 175.43B |
| Enterprise Value | 189.64B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | Aug 17, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 4.43B |
| Shares Change (YoY) | -0.14% |
| Shares Change (QoQ) | -0.29% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 27.49% |
| Float | 3.17B |
Ratios
| Measure | Value |
|---|
| PE Ratio | 10.16 |
| Forward PE | 11.94 |
| PS Ratio | 3.48 |
| Forward PS | 3.87 |
| PB Ratio | 5.19 |
| P/TBV Ratio | 11.57 |
| P/FCF Ratio | 15.50 |
| P/OCF Ratio | 8.91 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 10.66 |
| EV / Sales | 3.77 |
| EV / EBITDA | 7.15 |
| EV / EBIT | 7.69 |
| EV / FCF | 16.75 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.87 |
| Quick Ratio | 0.64 |
| Debt / Equity | 0.63 |
| Debt / EBITDA | 0.80 |
| Debt / FCF | 1.89 |
| Interest Coverage | 1,566.84 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 59.82% |
| Return on Assets (ROA) | 18.73% |
| Return on Invested Capital (ROIC) | 39.22% |
| Return on Capital Employed (ROCE) | 45.35% |
| Weighted Average Cost of Capital (WACC) | 5.68% |
| Revenue Per Employee | $754,734 |
| Profits Per Employee | $266,774 |
| Employee Count | 66,700 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 1.22 |
Taxes
| Measure | Value |
|---|
| Income Tax | 4.94B |
| Effective Tax Rate | 21.72% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.38 |
| 52-Week Price Change | -22.13% |
| 50-Day Moving Average | 41.23 |
| 200-Day Moving Average | 44.19 |
| Relative Strength Index (RSI) | 53.91 |
| Average Volume (20 Days) | 10,157,144 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 37.44M |
| Short Previous Month | 26.34M |
| Short % of Shares Out | 1.18% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.52 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 50.34B |
| Gross Profit | 41.27B |
| Operating Income | 24.66B |
| Pretax Income | 22.73B |
| Net Income | 17.79B |
| EBITDA | 26.54B |
| EBIT | 24.66B |
| Earnings Per Share (EPS) | $3.94 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 6.87B |
| Total Debt | 21.41B |
| Net Cash | -14.54B |
| Net Cash Per Share | -$3.28 |
| Equity (Book Value) | 33.81B |
| Book Value Per Share | 7.64 |
| Working Capital | -4.64B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 19.69B |
| Capital Expenditures | -8.37B |
| Depreciation & Amortization | 1.83B |
| Net Borrowing | 5.44B |
| Free Cash Flow | 11.32B |
| FCF Per Share | $2.56 |
Margins
| Measure | Value |
|---|
| Gross Margin | 81.99% |
| Operating Margin | 48.99% |
| Pretax Margin | 45.15% |
| Profit Margin | 35.35% |
| EBITDA Margin | 52.72% |
| EBIT Margin | 48.99% |
| FCF Margin | 23.02% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $1.28 |
| Dividend Yield | 3.20% |
| Dividend Growth (YoY) | 4.13% |
| Years of Dividend Growth | 6 |
| Payout Ratio | 32.54% |
| FCF Payout Ratio | 50.11% |
| Buyback Yield | 0.14% |
| Shareholder Yield | 3.34% |
| Earnings Yield | 9.84% |
| FCF Yield | 6.45% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $44.96 |
| Price Target Difference | 12.40% |
| Analyst Consensus | Hold |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 1.70% |
| EPS Growth Forecast (3Y) | 1.15% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 20, 2023 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 4.21 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |